Fig. 5. The antidepressant-like effects of intra-mPFC infusion of IGF-1 are not blocked by co-infusion of BDNF nAb.
a Experimental timeline for behavioral testing after intra-mPFC infusion of control IgG (200 ng/side), IGF-1 (50 ng/side) plus control IgG, or IGF-1 plus BDNF nAb (200 ng/side). b Immobility time in the forced swim test (FST) 1 day after intra-mPFC infusion (F2,18 = 7.12, p = 0.0053, n = 6–8). c Locomotor activity (LMA) 2 days after intra-mPFC infusion (F2,18 = 1.66, p = 0.218, n = 6–8). d Time spent sniffing female urine in the female urine sniffing test (FUST) 3 days after intra-mPFC infusion (F2,18 = 6.15, p = 0.0092, n = 6–8). e Latency to feed in the novelty-suppressed feeding (NSF) test 4 days after intra-mPFC infusion (F2,18 = 10.12, p = 0.0011, n = 6–8). f Home cage feeding (HCF) just after the NSF (F2,18 = 1.10, p = 0.354, n = 6–8). g Schematic representation of mPFC infusion sites. Plates are from ref. [50]; 1.94, 1.78, 1.70, and 1.54 indicate distances (mm) from bregma. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01 (one-way ANOVA followed by Tukey’s post hoc test).